Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene

BACKGROUND: Treatment options in metastatic breast cancer are limited. New therapies preferable with predictive biomarkers are needed. The aim of these trials was to investigate if gene copy number of the topoisomerase 1 gene was predictive of response to the topoisomerase inhibitor irinotecan. METH...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMC Cancer
Auteurs principaux: Kümler, Iben, Balslev, Eva, Stenvang, Jan, Brünner, Nils, Ejlertsen, Bent, Jakobsen, Erik Hugger, Nielsen, Dorte Lisbet
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2019
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6567440/
https://ncbi.nlm.nih.gov/pubmed/31196001
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5788-9
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires